🇺🇸 FDA
Pipeline program

Recombinant human tissue kallikrein

DM199-2016-001

Phase 1 small_molecule completed

Quick answer

Recombinant human tissue kallikrein for Stroke is a Phase 1 program (small_molecule) at DiaMedica Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
DiaMedica Therapeutics
Indication
Stroke
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials